HomeCrossing the Blood-Brain Barrier with Breakthrough Therapeutics AngioChem is a clinical-stage biotechnology company discovering and developing breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. The company’s proprietary platform for Engineered Peptide Compounds (EPiC) offers a completely new, innovative way to develop drugs to cross the blood-brain barrier and positions AngioChem as a leader in this field. Based on the EPiC platform, AngioChem has created a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases and related disorders, including brain cancer, cancer metastases, neurodegenerative and metabolic diseases. |
||
|
News & Events18-Oct-2009 // Angiochem’s ANG1005 demonstrates safety and efficacy in Phase 1/2 brain cancer studies READ More... 18-Oct-2009 // New research helps therapies get around, through blood-brain barrier (press release issued at Neuroscience 2009) READ MORE... 18-Oct-2009 // Three new posters presented at Society for Neuroscience meeting available for viewing on our Website. Read posters... |
||

